Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 5 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.

Novaferon demonstrates efficacy signal in COVID-19

21 Aug 2020

The recombinant antitumour/antiviral protein novaferon is used to treat hepatitis B virus in China, but a group of investigators finds a signal that it can do something else: induce viral clearance in COVID-19 patients.

The investigators evaluated the potency of novaferon against COVID-19 in vitro and in patients. Results of laboratory experiments were encouraging. The drug effectively inhibited viral replication within SARS-CoV-2-infected cells (EC50=1.02 ng/ml). Additionally, healthy cells incubated with novaferon resisted the entry of the virus (EC50=0.10 ng/ml).

In the trial, 89 COVID-19 patients with moderate or severe illness were randomized to receive novaferon monotherapy (n=30; median age, 46.5 years) or in combination with lopinavir–ritonavir (n=30; median age, 50.0 years), or lopinavir–ritonavir only (n=29; median age, 37.0 years). The median time from symptom onset to antiviral drug administration were 4, 7, and 4 days in the respective groups.

The primary endpoint of SARS-CoV-2 clearance rate at day 6 was higher in both novaferon monotherapy and combination arms than in the lopinavir–ritonavir-alone arm (50.0 percent and 60.0 percent vs 24.1 percent; p=0.0400 and p=0.0053, respectively). There was no significant difference between the two novaferon arms, indicating that the beneficial effect of the recombinant antitumour/antiviral protein on viral clearance does not differ when used alone or together with lopinavir–ritonavir.

Moreover, patients who received novaferon either as a monotherapy or combined with lopinavir–ritonavir achieved viral clearance 3 days earlier than those who received lopinavir–ritonavir alone (median, 6 days, 6 days, and 9 days, respectively).

None of the patients developed severe adverse events (AEs) associated with the tested antiviral drugs. AEs occurred in 83.3 percent of patients on novaferon, 83.3 percent on novaferon plus lopinavir–ritonavir, and 89.6 percent on lopinavir–ritonavir alone. The most common AEs were lymphopenia and loss of appetite in the first group, lymphopenia and cough in the second group, and fatigue and lymphopenia in the third group.

The present data justify further evaluation of novaferon for COVID-19 in large cohort studies.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 5 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.